Flecainide is effective for supraventricular arrhythmias but carries a significant risk of proarrhythmia in patients with prior myocardial infarction.
Answers are grounded in this paper and cite their sources.
Supports restricting flecainide to supraventricular arrhythmias without structural heart disease; reinforces CAST proarrhythmia findings.
Flecainide is a Class IC antiarrhythmic agent whose primary electrophysiologic effect is a slowing of conduction in a wide range of cardiac tissues. It is well absorbed and effective in suppressing isolated premature ventricular contractions (PVCs) or nonsustained ventricular arrhythmia but has only a modest efficacy when electrophysiologic testing is used as an endpoint. Its adverse effect on mortality in the CAST trial suggested a propensity to proarrhythmia--a phenomenon to which the Class IC agents appear particularly prone. Despite the applicability of the CAST study only to patients with a prior myocardial infarction, there has been a shift away from flecainide in ventricular arrhythmia, but the low noncardiac side effect profile of the agent allows for its continued use in a wide variety of supraventricular arrhythmias.
No takes yet. Share an insight, caveat, or question.
Falk et al. (1994) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: